Rimantadine: A Clinical Perspective

Wintermeyer, Susan M.; Nahata, Milap C.

doi:10.1177/106002809502900312

Cited by 83 publications

(37 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PAF caused a decrease in PAFr surface expression by 35 Ϯ 5% as compared with controls or amantadine or rimantadine alone (P Ͻ 0.05; n ϭ 4). Both amantadine and rimantadine (1 M) (an effective derivative of amantadine) significantly inhibited the loss of PAFr surface expression on PMNs (P Ͻ 0.05; n ϭ 4) (16,51,53,71).…”

Section: Amantadine and Hts Inhibit Paf-mediated Internalization Of Tmentioning

confidence: 99%

Amantadine inhibits platelet-activating factor induced clathrin-mediated endocytosis in human neutrophils

Eckels

Banerjee²,

Moore

et al. 2009

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

Silliman CC. Amantadine inhibits platelet-activating factor induced clathrin-mediated endocytosis in human neutrophils. Am J Physiol Cell Physiol 297: C886 -C897, 2009. First published March 18, 2009 doi:10.1152/ajpcell.00416.2008.-Receptor signaling is integral for adhesion, emigration, phagocytosis, and reactive oxygen species production in polymorphonuclear neutrophils (PMNs). Priming is an important part of PMN emigration, but it can also lead to PMNmediated organ injury in the host. Platelet-activating factor (PAF) primes PMNs through activation of a specific G protein-coupled receptor. We hypothesize that PAF priming of PMNs requires clathrin-mediated endocytosis (CME) of the PAF receptor (PAFr), and, therefore, amantadine, known to inhibit CME, significantly antagonizes PAF signaling. PMNs were isolated by standard techniques to Ͼ98% purity and tested for viability. Amantadine (1 mM) significantly inhibited the PAF-mediated changes in the cellular distribution of clathrin and the physical colocalization [fluorescence resonance energy transfer positive (FRET ϩ )] of early endosome antigen-1 and Rab5a, known components of CME and similar to hypertonic saline, a known inhibitor of CME. Furthermore, amantadine had no effect on the PAF-induced cytosolic calcium flux; however, phosphorylation of p38 MAPK was significantly decreased. Amantadine inhibited PAFmediated changes in PMN physiology, including priming of the NADPH oxidase and shape change with lesser inhibition of increases in CD11b surface expression and elastase release. Furthermore, rimantadine, an amantadine analog, was a more potent inhibitor of PAF priming of the N-formyl-methionyl-leucyl-phenylalanine-activated oxidase. PAF priming of PMNs requires clathrin-mediated endocytosis that is inhibited when PMNs are pretreated with either amantadine or rimantadine. Thus, amantadine and rimantadine have the potential to ameliorate PMN-mediated tissue damage in humans.

show abstract

Section: Amantadine and Hts Inhibit Paf-mediated Internalization Of Tmentioning

confidence: 99%

Amantadine inhibits platelet-activating factor induced clathrin-mediated endocytosis in human neutrophils

Eckels

Banerjee²,

Moore

et al. 2009

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

show abstract

“…Both amantadine and rimantadine are indicated for chemoprophylaxis of influenza A infection, but not influenza B (Table 3). Both drugs are approximately 60%–90% effective in preventing illness from influenza A infection (Wintermeyer and Nahata 1995; Demicheli et al 2000). Amantadine and rimantadine have been studied extensively among nursing home populations as a component of influenza outbreak-control programs, which can limit the spread of influenza within chronic-care institutions (Guay 1994; Wintermeyer and Nahata 1995).…”

Section: Antiviral Treatment and Chemoprophylaxismentioning

confidence: 99%

“…The majority of published reports showing the efficacy and effectiveness of antiviral agents to control influenza outbreaks are based, however, on studies carried out in nursing homes where amantadine and rimantadine were used to prevent influenza A infections (Patriarca et al 1987; Guay 1994; Wintermeyer and Nahata 1995). The prophylactic use of zanamivir and oseltamivir in nursing homes and among patients with chronic medical conditions is more limited, but their efficacy and effectiveness could be similar to that for amantadates (Bowles et al 2002; Schilling et al 1998; Lee et al 2000; Parker et al 2001).…”

Section: Antiviral Treatment and Chemoprophylaxismentioning

confidence: 99%

Prevention and control of influenza in persons with chronic obstructive pulmonary disease

Plans-Rubió¹

2007

International Journal of COPD

View full text Add to dashboard Cite

Despite recommendations for annual vaccination against influenza, more than half of patients with chronic obstructive pulmonary disease (COPD) in developed countries do not receive this vaccine. Influenza is characterized by its potentially of causing epidemics and by excess morbidity and mortality in patients with COPD and other chronic medical conditions. Good evidence of the efficacy, effectiveness, and cost-effectiveness of influenza vaccination underlines the recommendation of use in patients with COPD. Influenza vaccination could reduce influenza-related complications and exacerbations in patients with COPD, therefore reducing hospitalizations and deaths. Each year, all persons with COPD should be vaccinated with the inactivated trivalent influenza vaccine containing the most frequent two influenza A viral strains and one influenza B viral strain detected in the influenza season of the previous year. To achieve a 100% vaccination rate in patients with COPD, all patients with COPD registered in health insurance companies and attended in health centers and specialized clinics should be vaccinated during the immunization period (October–December). Antiviral therapies could be used as an adjunct to vaccination and to reduce influenza transmission in outbreaks. Antiviral therapies could reduce the duration and complications of influenza when administered within two days of the onset of illness. Research is necessary for new antiviral therapies that could prevent influenza with cost-effectiveness similar to the influenza vaccine.

show abstract

“…Rimantadine is also absorbed well; 75 percent of a dose is metabolized in the liver, mainly by hydroxylation. 48 Older adults require a reduction in the dose, presumably because of an agerelated decline in hepatic function. Both drugs are effective for the prevention and treatment of influenza A infections.…”

Section: Amantadine and Rimantadinementioning

confidence: 99%